12 August 2023: Clinical Research
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson’s Disease Treatment
Yusuke Nomoto ABCDEF* , Makoto Furihata ABCDEF , Haruka Hagiwara F , Hirotaka Ishino B , Shintaro Yano D , Hiroki Okawa B , Yoichi Nakatsu B , Kumiko Noda B , Shinjiro Nishi F , Shingo Ogiwara AB , Tsuneo Kitamura D , Taro Osada AGDOI: 10.12659/MSM.941285
Med Sci Monit 2023; 29:e941285
Table 6 Outcomes of PEG-J procedures.
| General outcomes of PEG-J procedures | |
|---|---|
| Procedure time | 21.7±12.5 (range: 8–51) min. |
| Hospital stay | 27.8±15.8 (range: 13–98) days |
| Successful rate | 100.0% (n=44/44 procedures) |
| Mortality rate | 0.0% (n=0/44 procedures) |
| Dropout rate (LCIG) | 16.3% (n=7/43 patients) |
| Observation period | 19 (median) (range: 3–40) months |
| Procedure-related AEs | 15.9% |
| Device-related AEs | 60.5% |
| PEG-J – percutaneous endoscopic transgastric jejunostomy; LCIG – levodopa-carbidopa intestinal gel; AE – adverse events. Data are presented as mean±standard deviation. | |